| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Departments of Cancer Biology [W. L., N. R., O. S., C. T., S. W., Y. D. J., F. F., A. T., M. A., M. B-E., G. E. G., L. M. E.] and Surgical Oncology [A. A. P., L. M. E.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B (NF-B) signaling pathways blocked the ability of IL-1ß to induce COX-2 mRNA. In contrast, Wortmannin, a phosphoinositide 3-kinase inhibitor upstream of protein kinase B/Akt, led to a slight increase in COX-2 mRNA expression after IL-1ß treatment. Electrophoretic mobility shift assay on nuclear extracts demonstrated that IL-1ß induced NF-B DNA binding activity in HT-29 cells, and the activated NF-B complex was eliminated after treatment with an inhibitor of NF-B. Supershift assay indicated that the two NF-B subunits, p65 and p50, were involved in activation of NF-B complex by IL-1ß stimulation. The stability of COX-2 mRNA was not altered by IL-1ß treatment. These data demonstrate that IL-1ß induces COX-2 expression in HT-29 cells through multiple signaling pathways and NF-B. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Various human tumor tissues have been reported to contain high concentrations of prostaglandins (2) . Recent experimental evidence suggests that COX-2 may play an important role in colorectal carcinogenesis (3) . COX-2 mRNA is overexpressed in 80–90% of human colorectal carcinomas and in 40–50% of premalignant adenomas (3 , 4) . COX-2 may contribute to the growth and metastatic potential of colorectal cancer by increasing expression of the antiapoptosis factor BCL-2 and up-regulating specific angiogenic factors (5 , 6) . A decrease in COX-2 activity results in decreased tumor growth in colorectal tumor models (COX-2 knockout mice and use of COX-2-selective inhibitors; Ref. 7 ). However, regulation of COX-2 in human colon cancer cells has not been fully elucidated.
The proinflammatory cytokine IL-1ß is synthesized in tumor-infiltrating immune cells as well as endothelial cells. Studies from our laboratory have demonstrated that IL-1ß induces expression of the potent angiogenic factors vascular endothelial growth factor and IL-8 in human colon cancer cells and pericytes (Refs. 8 , 9 and unpublished data). In this study, we investigated the effect of IL-1ß on COX-2 mRNA and protein expression in the human colorectal cell line HT-29. Furthermore, we investigated the mechanisms involved in COX-2 induction by IL-1ß.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Materials and Antibodies.
IL-1ß, epidermal growth factor, insulin-like growth factor-I, and TNF-
were purchased from R&D Systems, Inc. (Minneapolis, MN). Phosphorylated Erk 1/2 (Thr202/Tyr204), JNK (Thr183/Tyr185), P38 (Thr180/Tyr182) MAPK, Akt (Ser473) and total Erk 1/2, JNK, Akt, and P38 MAPK antibodies were obtained from Cell Signaling Technology, Inc. (Beverly, MA). SB203580 (P38 MAPK inhibitor) and SP600125 (JNK inhibitor) were purchased from Calbiochem Co. (La Jolla, CA). U0126 and PD98059 (MEK inhibitors) were purchased from New England Biolabs, Inc. (Beverly, MA). Actin antibody, Act D, Wortmannin, and TLCK were purchased from Sigma (St. Louis, MO). COX-2, NF-B, p65, p50, p52, c-Rel antibodies, and nonspecific rabbit IgG were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Western Blot Hybridization.
Cells were lysed with protein lysis buffer [20 mM sodium phosphate (pH 7.4), 150 mM sodium chloride, 1% Triton X-100, 5 mM EDTA, 5 mM phenylmethylsulfonyl fluoride, 1% aprotinin, 1 µg/ml leupeptin, and 500 µM Na3VO4].
The protein was subjected to electrophoresis on polyacrylamide gel and transferred to a nylon membrane (Millipore Corp., Bedford, MA) as described previously (9) . After blocking with 5% milk in 0.1% Tween 20 in PBS, the membranes were probed with primary antibodies. The membranes were then washed and treated with the secondary antibody labeled with horseradish peroxidase. Protein bands were visualized using a commercially available chemiluminescence kit (Amersham Corp.).
Isolation of mRNA and Northern Blot Analysis.
Total RNA was extracted from 80% confluent tumor cells growing in culture using TRIzol reagent according to the manufacturer’s protocol (Life Technologies, Inc.). Northern blot analysis was performed as described previously (9)
. Each cDNA probe was radiolabeled with [-32P]deoxyribonucleotide triphosphate by random primer technique using a commercially available kit (Amersham Corp.). After prehybridization of blots for 3–4 h at 65°C in rapid hybridization buffer (Amersham Corp.), the membranes were hybridized overnight at 65°C with the cDNA probe for COX-2 (Cayman Chemical Co.) or glyceraldehyde-3-phosphate dehydrogenase (internal control; American Type Culture Collection). The probed nylon membranes were washed at 65°C with 30 mM NaCl, 3 mM sodium citrate (pH 7.2), and 0.1% SDS. Autoradiography was then performed. Densitometric analysis was performed using NIH Image 1.62 software to quantify the results of Northern/Western blot analyses in the linear range of the film. Glyceraldehyde-3-phosphate dehydrogenase and actin were used as internal controls for loading.
Transcriptional Activity and mRNA Half-Life Studies.
To determine whether the increase in COX-2 mRNA in colon cancer cells was attributable to an increase in transcription, HT-29 cells were incubated in the presence or absence of Act D (5 µg/ml) for 2 h before exposure to IL-1ß, and total RNA was extracted from the cells after treatment with IL-1ß for 2 h. Control cells were treated with Act D without IL-1ß. To investigate the effect of IL-1ß on the half-life of COX-2 mRNA, HT-29 cells were incubated in the presence or absence of IL-1ß (10 ng/ml) for 2 h. Additional transcription was blocked by adding Act D (5 µg/ml). Total RNA was extracted from the cells at 0, 0.5, 1.5, 3, 6, and 24 h after the addition of Act D, and Northern blot analysis was done. The half-life of COX-2 mRNA was determined by plotting relative COX-2 mRNA expression levels on a semilogarithmic axis versus time (Cricket Software, Malvern, PA).
Extraction of Nuclear Protein and Electrophoretic Mobility Shift Assay.
HT-29 cells (80% confluent) were incubated in 5% fetal bovine serum-containing medium overnight and then treated with IL-1ß (10 ng/ml) for indicated time points. Nuclear protein extraction and EMSA were performed as described previously (9)
. EMSA was performed with the Gel Shift Assay System (Promega, Madison, WI). Briefly, oligonucleotide containing the consensus sequence for NF-B (5'-AGTTGAGGGGACTTTCCCAGG-3') was end-labeled with [
-32P]AMP (3000 Ci/mmol; Amersham Corp.) using T4 polynucleotide kinase and was then purified in Microspin G-25 columns (Sigma) and used as probes for EMSA. The gel was dried and subjected to autoradiography. In competition studies, a 100-fold excess of unlabeled oligonucleotide was included in the reaction mixture along with the radiolabeled probe. For supershift experiments, affinity-purified rabbit antibodies (2 µg/reaction) to p50, p65, p52, and c-Rel and nonspecific IgG were incubated in the standard reaction mixture at room temperature for 45 min before the labeled oligonucleotide was added.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
for various times. Expression of COX-2 mRNA increased after incubation of HT-29 cells with either IL-1ß or TNF-. Expression was highest at 4 h and remained elevated by 24 h (Fig. 1)
. To confirm that this finding was not restricted to a single cell line, we examined COX-2 expression in a second colon cancer cell line, KM12L4. Similar to results with HT-29 cells, IL-1ß and TNF- increased COX-2 mRNA expression in KM12L4 cells (data not shown).
|
6-fold at 1 h (Fig. 2A)
, and it remained increased by at least 4-fold for up to 24 h. Similarly, COX-2 protein expression was increased 2–3-fold by 1–2 h with IL-1ß treatment and increased to 5-fold at 24 h (Fig. 2B)
. To examine the effect of the dose of IL-1ß on COX-2 expression, HT-29 cells were incubated in various concentrations of IL-1ß for 2 h (COX-2 mRNA) or 4 h (COX-2 protein). COX-2 mRNA expression was increased after incubation of cells with IL-1ß at 1 ng/ml, with no additional increase observed at higher concentrations (Fig. 3A)
. COX-2 protein expression was increased after incubation with 1 ng/ml and remained elevated at higher doses of IL-1ß (Fig. 3B)
.
|
|
. The phosphorylation of JNK was induced within 30 min and had returned to the basal level by 60 min. Phosphorylation of Akt was essentially unchanged by IL-1ß treatment. The phosphorylation of P38 MAPK was not induced by IL-ß (Fig. 4)
.
|
.
|
. SB203580 at similar doses inhibited constitutive P38 activation by 40–60% (data not shown).
Effects of IL-1ß on Transcriptional Activity and mRNA Half-Life.
To determine the mechanism by which IL-1ß induced COX-2 mRNA expression, transcription was blocked with Act D in HT-29 cells before the addition of IL-1ß. This blockade of transcription completely abolished induction of COX-2 mRNA by IL-1ß (Fig. 6)
. To determine the effect of IL-1ß on the half-life of COX-2 mRNA, HT-29 cells were incubated in the presence or absence of IL-1ß for various times, and additional transcription was blocked with Act D. The half-life of COX-2 mRNA was similar to that in cells treated with IL-1ß as in controls (data not shown).
|
B Activation and Effect of Inhibition of NF-B on COX-2 mRNA Expression.B, EMSA was performed on nuclear extracts from HT-29 cells incubated with IL-1ß (10 ng/ml) for 0, 30, 60, 90, or 120 min, and the consensus oligonucleotides for the NF-B binding sites were used as labeled probes. The transcription factor NF-B was translocated by IL-1ß treatment at 30 min. Activation of NF-B was inhibited by the NF-B-specific inhibitor TLCK (Fig. 7A)
. Supershift assay indicated that both NF-B subunits, p65 and p50, were induced by IL-1ß (Fig. 7B)
.
|
B pathway in COX-2 mRNA induction, HT-29 cells were pretreated with three NF-B inhibitors (TLCK, N--tosylphenylalanyl-chloromethyl ketone, and pyrrolidine dithiocarbamate) 1 h before treatment with IL-1ß. All three NF-B inhibitors blocked COX-2 induction in a dose-dependent fashion (data not shown). |
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
IL-1ß is a potent immunoregulatory and proinflammatory cytokine. Recently, IL-1ß levels were associated with macrophage infiltration and angiogenin levels in human colon cancer (18) . Two basic IL-1 receptors have been identified. The IL-1 type I receptor initiates signal transduction upon binding its ligand (19) , whereas the type II receptor, which lacks an intracellular signaling domain, does not transduce a signal. We have previously shown by using reverse transcriptase-PCR that both HT-29 and KM12L4 colon cancer cells express the mRNA for the type I receptor (data not shown).
IL-1ß signaling involves numerous intracellular mediators, including the Erk 1/2, JNK, P38 MAPK, and PKB/Akt pathways (20
, 21) . Several signaling pathways have been implicated in the regulation of COX-2 expression by IL-1ß. In human gastric cancer cells, both P38 MAPK and Erk 1/2 are upstream signaling intermediates that regulate induction of COX-2 expression by IL-1ß (22)
. Regulation of COX-2 induction is also dependent on the activation of protein kinase C in human endothelial cells (23)
. Guan et al. (24)
have demonstrated that JNK/stress-activated protein kinase and P38 MAPK signaling cascades are required for IL-1ß-induced COX-2 expression and prostaglandin E2 synthesis in rat renal mesangial cells. To determine the signaling pathways that mediate induction of COX-2 by IL-1ß in HT-29 human colon cancer cells, we determined the signaling intermediates that were activated upon IL-1ß induction. We then used pharmacological inhibitors of various signaling pathways to determine whether blockade of the activity of specific pathways would block induction of COX-2 by IL-1ß. We found that inhibition of Erk 1/2, JNK, and P38 MAPK signaling pathways blocked IL-1ß COX-2 expression. It has previously been demonstrated that activation of NF-B leads to induction of COX-2 in macrophages, colon, and lung epithelial cells (25, 26, 27)
. Consistent with this finding, our data indicate that the use of NF-B inhibitors can block COX-2 induction by IL-1ß.
In the HT–29 colon cancer cell line that we used in the current study, others have shown that inhibition of PI3k can activate NF-B binding ability (28)
. Our studies demonstrated that the PI3k inhibitor Wortmannin led to induction of COX-2 mRNA (Fig. 5A)
, and IL-1ß activated both the PI3k/Akt and NF-B pathways in HT-29 colon cancer cells. On the basis of the above, the PI3k pathway might negatively regulate COX-2 expression. The blockade of the PI3k pathway may increase NF-B binding, which in turn may up-regulate COX-2 expression.
In conclusion, our study demonstrates that multiple signaling pathways are involved in COX-2 induction by IL-1ß, including the Erk 1/2, JNK, and P38 MAPK. Although IL-1ß did not lead to P38 activation, COX-2 induction by IL-1ß was dependent upon constitutive P38 MAPK activity as an inhibitor of P38 activity blocked COX-2 induction by IL-1ß (Fig. 8)
. Our study also demonstrated that the transcription factor NF-B is involved in COX-2 induction by IL-1ß. Thus, targeting the pathways that mediate COX-2 may be useful as a component of therapeutic strategies in patients with colon cancer.
|
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This work was supported, in part, by grants from the Jon and Susie Hall Fund for Colon Cancer Research (to L. M. E.) and the Gillson Longenbaugh Foundation (to L. M. E., G. E. G.), NIH Grant T-32 CA 09599 (to A. A. P.), NIH 2RO-1 Grant CA55627 (to G. E. G.), and NIH Cancer Center Support Grant CA16672. 
2 To whom requests for reprints should be addressed, at Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030-4009. Phone: (713) 792-6926; Fax: (713) 792-4689; E-mail: lellis{at}mdanderson.org
3 The abbreviations used are: COX, cyclooxygenase; IL, interleukin; TNF-, tumor necrosis factor ; ERK, extracellular signal-regulated kinase; JNK, c-Jun NH2-terminal kinase; Act D, actinomycin D; MAPK, mitogen-activated protein kinase; MEK, MAP/ERK kinase; TLCK, N-tosyl-Lys-chloromethyl ketone; NF-B, nuclear factor-B; EMSA, electrophoretic mobility shift analysis; PI3k, phosphatidylinositol 3'-kinase.
Received 10/29/02. Accepted 4/24/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.[Medline]
B in interleukin-1ß induced IL-8 expression in human vascular smooth muscle cells. Cytokine, 18: 206-213, 2002.[Medline]
B in human endothelial cells. J. Biol. Chem., 275: 15458-15465, 2000.B in the transcriptional control of COX-2 gene expression by IL-1ß. Biochem. Biophys. Res. Commun., 237: 28-32, 1997.[Medline]
B in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett., 418: 175-178, 1997.[Medline]
B activation via the NIK/IKK signalling complex. Oncogene, 18: 6013-6020, 1999.[Medline]
B binding in HT-29 colon cancer cells by inhibition of phosphatidylinositol 3-kinase. Biochem. Biophys. Res. Commun., 273: 853-858, 2000.[Medline]This article has been cited by other articles:
|
|
 |
|
  S. Paul, A. M. Rimando, H. J. Lee, Y. Ji, B. S. Reddy, and N. Suh Anti-inflammatory Action of Pterostilbene Is Mediated through the p38 Mitogen-Activated Protein Kinase Pathway in Colon Cancer Cells Cancer Prevention Research, July 1, 2009; 2(7): 650 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Lee and E. P. Kay Common and Distinct Pathways for Cellular Activities in FGF-2 Signaling Induced by IL-1{beta} in Corneal Endothelial Cells Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2067 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Duffield-Lillico, J. O. Boyle, X. K. Zhou, A. Ghosh, G. S. Butala, K. Subbaramaiah, R. A. Newman, J. D. Morrow, G. L. Milne, and A. J. Dannenberg Levels of Prostaglandin E Metabolite and Leukotriene E4 Are Increased in the Urine of Smokers: Evidence that Celecoxib Shunts Arachidonic Acid into the 5-Lipoxygenase Pathway Cancer Prevention Research, April 1, 2009; 2(4): 322 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-C. Jang, S.-H. Sung, J.-G. Park, J.-W. Park, J. H. Bae, D. H. Shin, G.-Y. Park, S.-B. Han, and S.-I. Suh Glucosamine Hydrochloride Specifically Inhibits COX-2 by Preventing COX-2 N-Glycosylation and by Increasing COX-2 Protein Turnover in a Proteasome-dependent Manner J. Biol. Chem., September 21, 2007; 282(38): 27622 - 27632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wohlschlaeger, K. J. Schmitz, J. Palatty, A. Takeda, N. Takeda, C. Vahlhaus, B. Levkau, J. Stypmann, C. Schmid, K. W. Schmid, et al. Roles of cyclooxygenase-2 and phosphorylated Akt ( T hr308) in cardiac hypertrophy regression mediated by left-ventricular unloading J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Yan, R. R. Joseph, J. Wang, and A. W. Stadnyk Differential Pattern of Inflammatory Molecule Regulation in Intestinal Epithelial Cells Stimulated with IL-1 J. Immunol., October 15, 2006; 177(8): 5604 - 5611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tammali, K. V. Ramana, S. S. Singhal, S. Awasthi, and S. K. Srivastava Aldose Reductase Regulates Growth Factor-Induced Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Human Colon Cancer Cells Cancer Res., October 1, 2006; 66(19): 9705 - 9713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Koon, D. Zhao, Y. Zhan, S. H. Rhee, M. P. Moyer, and C. Pothoulakis Substance P Stimulates Cyclooxygenase-2 and Prostaglandin E2 Expression through JAK-STAT Activation in Human Colonic Epithelial Cells. J. Immunol., April 15, 2006; 176(8): 5050 - 5059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Thiel, M. Heinonen, J. Rintahaka, T. Hallikainen, A. Hemmes, D. A. Dixon, C. Haglund, and A. Ristimaki Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells J. Biol. Chem., February 24, 2006; 281(8): 4564 - 4569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ha, J.-H. Lee, H.-N. Kim, H.-M. Kim, H. B. Kwak, S. Lee, H.-H. Kim, and Z. H. Lee {alpha}-Lipoic Acid Inhibits Inflammatory Bone Resorption by Suppressing Prostaglandin E2 Synthesis J. Immunol., January 1, 2006; 176(1): 111 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wu, R. A. Silbajoris, Y. E. Whang, L. M. Graves, P. A. Bromberg, and J. M. Samet p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L883 - L889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-T. Lin, C.-Y. Zuon, C.-C. Chang, S.-T. Chen, C.-P. Chen, B.-R. Lin, M.-Y. Wang, Y.-M. Jeng, K.-J. Chang, P.-H. Lee, et al. Cyr61 Induces Gastric Cancer Cell Motility/Invasion via Activation of the Integrin/Nuclear Factor-{kappa}B/Cyclooxygenase-2 Signaling Pathway Clin. Cancer Res., August 15, 2005; 11(16): 5809 - 5820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hall-Pogar, H. Zhang, B. Tian, and C. S. Lutz Alternative polyadenylation of cyclooxygenase-2 Nucleic Acids Res., May 4, 2005; 33(8): 2565 - 2579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Gauthier, C. R. Pickering, C. J. Miller, C. A. Fordyce, K. L. Chew, H. K. Berman, and T. D. Tlsty p38 Regulates Cyclooxygenase-2 in Human Mammary Epithelial Cells and Is Activated in Premalignant Tissue Cancer Res., March 1, 2005; 65(5): 1792 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Hung, I.-J. Su, H.-Y. Lei, H.-C. Wang, W.-C. Lin, W.-T. Chang, W. Huang, W.-C. Chang, Y.-S. Chang, C.-C. Chen, et al. Endoplasmic Reticulum Stress Stimulates the Expression of Cyclooxygenase-2 through Activation of NF-{kappa}B and pp38 Mitogen-activated Protein Kinase J. Biol. Chem., November 5, 2004; 279(45): 46384 - 46392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ishimura, S. F. Bronk, and G. J. Gores Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G88 - G95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Schonthal, C. R. Herzog, M. V. Swamy, and C. V. Rao Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53. Cancer Res 2003;63:5239-42. Cancer Res., April 15, 2004; 64(8): 2937 - 2938. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
